An Investigation of the Combination of Y15 and Metformin for the Treatment of Platinum-Resistant Ovarian Cancer
ISEF · 2024 Translational Medical Science
Overview
The objective of this study was to investigate the effect of Metformin, the effect of Y15, and the combinational effect of Y15 and Metformin for the treatment of platinum-resistant ovarian cancer (PROC). The results of this study demonstrated that both Metformin and Y15 have dose-dependent effects on cell viability, and IC50 for Metformin is much higher than Y15, suggesting that Y15 is more effective in inhibiting cell viability. The combination treatment significantly reduced cell viability in PROC OVCAR 3 cells. These findings offer promising insights into exploring this drug combination for the treatment of PROC.
Awards (1)
- Long Island University: Presidential Scholarships
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2023
The Effects of APC Loss on Response to Chemotherapy in Ovarian Cancer Cells
ISEF · 2025
Overcoming Docetaxel Resistance in Prostate Cancer
ISEF · 2018
Cytotoxic Effects of Sulindac, Metformin, and TBHP on in vitro Lung Cancer Cells and the Effects of Glucose Level on Efficiency of the Treatment
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair